Canagliflozin in combination therapy for treating type 2 diabetes

Review proposal consultation

Stakeholder matrix (PDF 259 KB)

Diabetes (type 2) - canagliflozin: equality impact assessment - guidance review

Diabetes (type 2) - canagliflozin: final appraisal determination information

Diabetes (type 2) - canagliflozin: FAD document

Diabetes (type 2) - canagliflozin: FAD document (PDF 457 KB)

Diabetes (type 2) - canagliflozin: evaluation report information

Diabetes (type 2) - canagliflozin: appraisal consultation

Diabetes (type 2) - canagliflozin: appraisal consultation document information

Diabetes (type 2) - canagliflozin: evaluation report information

Diabetes (type 2) - canagliflozin: Equality Impact Assessment - scoping

Diabetes (type 2) - canagliflozin: response to consultee and commentator comments on the draft scope and provisional matrix

Diabetes (type 2) - canagliflozin: final scope 

Diabetes (type 2) - canagliflozin:final matrix 

Diabetes (type 2) - canagliflozin: draft scope - (pre referral)

Diabetes (type 2) - canagliflozin: provisional matrix - (pre referral)